A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants

Inclusion Criteria: * Are capable of giving signed informed consent and comply with the requirements and restrictions listed in the ICF and in this protocol. * Male or female participants aged 18 to 55 years in part A, C, D. Female participants aged 45 to 75 years in Part B. * Have a BMI within the range of 25.0 to 40.0 kg/m2 in Parts A, C, and D and a BMI within the range of 20.0 to 35.0 kg/m2 in Part B. * Participants without childbearing potential or Participants with childbearing potential, non-pregnant, non-lactating, must agree to use two forms of effective methods of contraception (at least one form must be highly effective) . * Male participants with female partners of childbearing potential must agree to use adequate methods of contraception. Male subjects are not allowed to donate sperm during this trial. * Are overtly healthy participants or Have FSH levels ≥ 40 IU/L at screening (Part B only). * Are willing to make themselves available for study visits for the duration of the study and are willing to follow study procedures. Exclusion Criteria: * Have a history or presence of clinically significant medical condition(s). * Have a history of any malignancy within the past 5 years. other than basal cell or squamous epithelial carcinomas in situ and cervical carcinoma in situ that have been resected with no evidence of metastatic diseases for 3 years. * Have a fasting serum triglyceride level of more than 500 mg/dL(5.6 mmol/L) at screening. * Estimated glomerular f…